A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Mission We are a data-first generative AI drug creation company with the mission to design differentiated antibody therapeutics. Our Integrated Drug Creation platform comprises, in part, cutting edge generative AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets. Antibody therapeutics represent a growing market and significant medical opportunity, yet the biopharmaceutical industry faces challenges in bringing these potentially life-changing medicines to patients. Leveraging our synthetic biology roots, we expect our Integrated Drug Creation platform to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. Through these efforts, we aim to shorten time to clinic, while increasing the probability of success.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 2.8M | - | - | - | - | - |
| Net Income | -115M | -103M | -111M | -105M | -103M | -49M |
| EPS | $-0.91 | $-0.94 | $-1.20 | $-1.15 | $-2.08 | $-3.19 |
| Free Cash Flow | -82M | -73M | -65M | -98M | -99M | -13M |
| ROIC | -162.5% | -57.2% | -61.1% | -37.1% | -28.1% | -11.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.01 | 0.03 | 0.03 | 0.00 | -0.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -119M | -109M | -116M | -107M | -75M | -13M |
| Operating Margin | -4229.1% | - | - | - | - | - |
| ROE | -54.5% | -58.0% | -62.8% | -38.2% | -28.2% | - |
| Shares Outstanding | 150M | 110M | 92M | 91M | 50M | 93M |
| Metric | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | 2.8M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -13M | -75M | -107M | -116M | -109M | -119M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | -4229.1% |
| Net Income | -49M | -103M | -105M | -111M | -103M | -115M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -4071.2% |
| Non-Recurring | 0 | 0 | 0 | 21M | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -11.9% | -28.1% | -37.1% | -61.1% | -57.2% | -162.5% |
| ROE | N/A | -28.2% | -38.2% | -62.8% | -58.0% | -54.5% |
| ROA | -55.9% | -24.2% | -32.7% | -50.9% | -47.9% | -46.8% |
| Cash Flow | ||||||
| Op. Cash Flow | -11M | -61M | -81M | -65M | -72M | -81M |
| Free Cash Flow | -13M | -99M | -98M | -65M | -73M | -82M |
| Owner Earnings | -13M | -78M | -107M | -90M | -105M | -114M |
| CapEx | 2.2M | 38M | 16M | 860K | 404K | 1.2M |
| Maint. CapEx | 1.1M | 6.7M | 13M | 14M | 13M | 13M |
| Growth CapEx | 1.1M | 31M | 3.1M | 0 | 0 | 0 |
| D&A | 1.1M | 6.7M | 13M | 14M | 13M | 13M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 420K | 11M | 13M | 11M | 19M | 19M |
| Debt Repayment | 500K | 1.6M | 4.7M | 3.0M | 3.4M | 3.4M |
| Balance Sheet | ||||||
| Net Debt | -66M | -251M | -52M | -68M | -40M | -152M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | 152M |
| Long-Term Debt | 4.1M | 1.1M | 8.0M | 4.7M | 1.3M | 1.3M |
| Debt/Equity | -0.05 | 0.00 | 0.03 | 0.03 | 0.01 | 0.00 |
| Interest Coverage | -21.0 | -21.9 | -109.8 | -114.4 | -192.7 | -192.7 |
| Equity | -89M | 366M | 274M | 176M | 179M | 210M |
| Total Assets | 89M | 426M | 321M | 217M | 214M | 245M |
| Total Liabilities | 22M | 60M | 47M | 41M | 34M | 35M |
| Intangibles | 0 | 76M | 73M | 97M | 90M | 90M |
| Retained Earnings | -90M | -191M | -296M | -406M | -510M | -510M |
| Working Capital | 63M | 239M | 157M | 91M | 105M | 105M |
| Current Assets | 73M | 273M | 187M | 121M | 134M | 134M |
| Current Liabilities | 10M | 34M | 30M | 30M | 29M | 29M |
| Per Share Data | ||||||
| EPS | -3.19 | -2.08 | -1.15 | -1.20 | -0.94 | -0.91 |
| Owner EPS | -0.13 | -1.57 | -1.17 | -0.98 | -0.96 | -0.76 |
| Book Value | -0.96 | 7.38 | 3.01 | 1.91 | 1.63 | 1.40 |
| Cash Flow/Share | -0.12 | -1.22 | -0.89 | -0.70 | -0.66 | -0.67 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 92.8M | 49.6M | 91.2M | 92.1M | 109.7M | 150.4M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -3.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 1.1 | 0.7 | 2.4 | 1.7 | 2.2 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | 162.9 |
| FCF Yield | N/A | -24.5% | -51.1% | -15.5% | -24.0% | -17.9% |
| Market Cap | N/A | 402M | 191M | 424M | 304M | 459M |
| Avg. Price | N/A | 15.09 | 4.87 | 1.90 | 4.17 | 3.05 |
| Year-End Price | N/A | 8.10 | 2.09 | 4.60 | 2.77 | 3.05 |
Absci Corp passes 0 of 9 quality checks, indicating weak fundamentals.
Absci Corp (ABSI) has a 5-year average return on invested capital (ROIC) of -39.1%. This is below average and may indicate limited pricing power.
Absci Corp (ABSI) has a market capitalization of $459M. It is classified as a small-cap stock.
Absci Corp (ABSI) does not currently pay a regular dividend.
Absci Corp (ABSI) operates in the Services-Commercial Physical & Biological Research industry, within the Industrials sector.
Absci Corp (ABSI) generated $-73 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Absci Corp (ABSI) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
Absci Corp (ABSI) reported earnings per share (EPS) of $-0.94 in its most recent fiscal year.
Absci Corp (ABSI) has a return on equity (ROE) of -58.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 5 years of financial data for Absci Corp (ABSI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Absci Corp (ABSI) has a book value per share of $1.63, based on its most recent annual SEC filing.
No recent press releases.